Non-motor manifestations in patients with Parkinson's disease
https://doi.org/10.21886/2712-8156-2021-2-4-73-78
Abstract
Objective: to study the structure of NMS, their frequency and clinical significance at all stages of PD; to conduct a comparative analysis of the structure of NMS in PD, depending on the stage, form of the disease and gender characteristics of patients.
Material and methods: examined 100 patients with PD, 31 patients as the control, and 11 patients as the comparison with Parkinson’s syndrome. The severity of movement disorders was assessed using the Hen and Yar scale. All patients with PD were also clinically assessed according to the UPDRS scale (parts II, III). Cognitive functions were assessed according to the Montreal CI scale (MOCA). The patients’ neuropsychological status was assessed using the Hospital Anxiety and Depression Scale (HADS).
Results: vegetative disorders are a frequent manifestation of PD; they differ significantly depending on the gender of the patient and on the stage of the disease. In 20% of patients with PD clinically pronounced depression and severe cognitive impairment were revealed.
Conclusion: non‑motor disorders are distinguished by a wide variety of manifestations and combinations, and their structure changes significantly from early to late stages of PD. The presence of NMS is an obligatory sign of PD. Although the structure of non‑motor manifestations of the disease is not specific, attention is drawn to the combination of more than ten different NMS in most patients, which does not occur with natural aging.
About the Authors
Z. A. Goncharova
Rostov State Medical University
Russian Federation
Russian Federation
Zoya A. Goncharova, Dr. Sci. (Med.); Associate Professor; Professor of Department of Nervous Diseases and Neurosurgery
Rostov-on-Don
M. A. Gelpey
Rostov State Medical University
Russian Federation
Russian Federation
Margarita A. Gelpey, neurologist
Rostov-on-Don
H. M. Mutalieva
Rostov State Medical University
Russian Federation
Russian Federation
Hаadi M. Mutalieva, Post-graduate of Department of Nervous Diseases and Neurosurgery
Rostov-on-Don
References
1. Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017;124 (8):901–905. DOI: 10.1007/s00702-017-1686-y.
2. Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW, et al. Prevalence of Parkinson’s disease across North America. Npj Parkinson’s Disease. 2018;4 (1):1–7. DOI: 10.1038/s41531-018-0058-0
3. Селиверстов Ю. А., Иллариошкин С. Н. Распространенность и основные способы терапии поздних стадий болезни Паркинсона. Журнал неврологии и психиатрии им. С. С. Корсакова. 2013;113 (11):100–106. Elibrary ID: 21088981
4. Гончарова З. А., Рабаданова Е. А., Гельпей М. А. Эпидемиологический анализ болезни Паркинсона в Ростове-на-Дону. Саратовский научно-медицинский журнал. 2017;13 (1):135–139. Elibrary ID: 29243350
5. Chen JJ. Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment. Am J Manag Care. 2010;16 Suppl Implications: S87–93. PMID: 20297871.
6. Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol. 2020;27 (1):27–42. DOI: 10.1111/ene.14108.
7. Cotzias GC. L-Dopa for Parkinsonism. N Engl J Med. 1968;278 (11):630. DOI: 10.1056/nejm196803142781127.
8. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol. 1969;21 (4):343–54. DOI: 10.1001/archneur.1969.00480160015001.
9. Benazzouz A, Gross C, Féger J, Boraud T, Bioulac B. Reversal of Rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur J Neurosci. 1993;5 (4):382–9. DOI: 10.1111/j.1460-9568.1993.Tb00505.x.
10. Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas JF, Broussolle E, et al. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet. 1995;345 (8942):91–5. DOI: 10.1016/s0140-6736(95)90062-4.
11. Iranzo A, Molinuevo JL, Santamaría J, Serradell M, Martí MJ, Valldeoriola F, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol. 2006;5 (7):572–7. DOI: 10.1016/S1474-4422 (06)70476-8.
12. Iranzo A, Serradell M, Vilaseca I, Valldeoriola F, Salamero M, Molina C, et al. Longitudinal assessment of olfactory function in idiopathic REM sleep behavior disorder. Parkinsonism Relat Disord. 2013;19 (6):600–4. DOI: 10.1016/j.parkreldis.2013.02.009.
13. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24 (2):197–211. DOI: 10.1016/s0197-4580 (02)00065-9.
14. Нодель М. Р. Депрессия при болезни Паркинсона как ведущий фактор ухудшения качества жизни. Медицинский Совет. 2013; (4):36–41. Elibrary ID: 21168625
15. Broen MPG, Leentjens AFG, Hinkle JT, Moonen AJH, Kuijf ML, Fischer NM, et al. Clinical Markers of Anxiety Subtypes in Parkinson Disease. J Geriatr Psychiatry Neurol. 2018;31 (2):55–62. DOI: 10.1177/0891988718757369.
16. Гончарова З. А., Гельпей М. А., Рабаданова Е. А. Влияние немоторных симптомов на течение болезни Паркинсона и качество жизни пациентов. Саратовский научно-медицинский журнал. 2016;12 (3):362–366. Elibrary ID: 28802368
17. Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, et al. MDS Task Force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI. Mov Disord. 2011;26 (10):1814– 24. DOI: 10.1002/mds.23823.
18. Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010;75 (12):1062–9. DOI: 10.1212/WNL.0b013e3181f39d0e.
19. Aarsland D, Brønnick K, Fladby T. Mild cognitive impairment in Parkinson’s disease. Curr Neurol Neurosci Rep. 2011;11 (4):371–8. DOI: 10.1007/s11910-011-0203-1.
20. Marsot A, Guilhaumou R, Azulay JP, Blin O. Levodopa in Parkinson’s Disease: A Review of Population Pharmacokinetics/Pharmacodynamics Analysis. J Pharm Pharm Sci. 2017;20 (0):226–238. DOI: 10.18433/J30H04.
21. Kehagia AA, Housden CR, Regenthal R, Barker RA, Müller U, Rowe J, et al. Targeting impulsivity in Parkinson’s disease using atomoxetine. Brain. 2014;137 (Pt 7):1986–97. DOI: 10.1093/brain/awu117.
22. Hanagasi HA, Tufekcioglu Z, Emre M. Dementia in Parkinson’s disease. J Neurol Sci. 2017;374:26–31. DOI: 10.1016/j.Jns.2017.01.012.
23. Sauerbier A, Jenner P, Todorova A, Chaudhuri KR. Non motor subtypes and Parkinson’s disease. Parkinsonism Relat Disord. 2016;22 Suppl 1: S41–6. DOI: 10.1016/j.Parkreldis.2015.09.027.
24. Cersosimo MG, Raina GB, Pecci C, Pellene A, Calandra CR, Gutiérrez C, et al. Gastrointestinal manifestations in Parkinson’s disease: prevalence and occurrence before motor symptoms. J Neurol. 2013;260 (5):1332–8. DOI: 10.1007/s00415-012-6801-2.
25. Wang G, Wan Y, Cheng Q, Xiao Q, Wang Y, Zhang J, et al. Malnutrition and associated factors in Chinese patients with Parkinson’s disease: Results from a pilot investigation. Parkinsonism Relat Disord. 2010;16 (2):119–23. DOI: 10.1016/j.Parkreldis.2009.08.009.
26. Jost WH. Gastrointestinal dysfunction in Parkinson’s Disease. J Neurol Sci. 2010;289 (1–2):69–73. DOI: 10.1016/j.Jns.2009.08.020.
27. Winge K, Skau AM, Stimpel H, Nielsen KK, Werdelin L. Prevalence of bladder dysfunction in Parkinsons disease. Neurourol Urodyn. 2006;25 (2):116–22. DOI: 10.1002/nau.20193.
28. Blackett H, Walker R, Wood B. Urinary dysfunction in Parkinson’s disease: a review. Parkinsonism Relat Disord. 2009;15 (2):81–7. DOI: 10.1016/j.parkreldis.2007.10.016.
29. Winge K, Friberg L, Werdelin L, Nielsen KK, Stimpel H. Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson’s disease. Eur J Neurol. 2005;12 (11):842–50. DOI: 10.1111/j.1468-1331.2005.01087.x.
30. Menza M, Dobkin RD, Marin H, Bienfait K. Sleep disturbances in Parkinson’s disease. Mov Disord. 2010;25 Suppl 1 (Suppl 1): S117–22. DOI: 10.1002/mds.22788.
31. Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, Mitra T, Frades-Payo B, Tluk S, et al. The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord. 2010;25 (6):704–9. DOI: 10.1002/mds.22868.
32. Титова Н. В., Катунина Е. А. Современные возможности улучшения качества жизни пациентов на поздних стадиях болезни Паркинсона. Журнал неврологии и психиатрии им. С. С. Корсакова. 2015;115 (3):94–99. DOI: 10.17116/jnevro20151153194-100
33. Нодель М. Р., Яхно Н. Н. Недвигательные нарушения при болезни Паркинсона и их влияние на качество жизни. В кн.: Болезнь Паркинсона и расстройства движений: руководство для врачей по материалам I Национального конгресса. М., 2008.
Review
For citations:
Goncharova Z.A., Gelpey M.A., Mutalieva H.M. Non-motor manifestations in patients with Parkinson's disease. South Russian Journal of Therapeutic Practice. 2021;2(4):73-78. (In Russ.) https://doi.org/10.21886/2712-8156-2021-2-4-73-78
Views:
986
Email this article 